Cardiovascular disease in obstructive sleep apnoea syndrome: The role of intermittent hypoxia and inflammation

European Respiratory Journal

Volumn 33, Issue 5, 2009, Pages 1195-1205

  Garvey, J F ^a,b   Taylor, C T ^b   McNicholas, W T ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cardiovascular disease; Hypoxia; Inflammation; Nuclear factor kB; Obstructive sleep apnoea syndrome; Review

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; ERYTHROPOIETIN; ETANERCEPT; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID BODY; DISEASE PREDISPOSITION; ENDOTHELIUM CELL; HUMAN; HYPOXEMIA; HYPOXIA; INFLAMMATION; MONOCYTE; NONHUMAN; PATHOGENESIS; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REOXYGENATION; SLEEP APNEA SYNDROME; T LYMPHOCYTE; WHITE ADIPOSE TISSUE;

ANIMALS; ANOXIA; CARDIOVASCULAR DISEASES; CYTOKINES; HUMANS; INFLAMMATION; SLEEP APNEA, OBSTRUCTIVE; TRANSCRIPTION FACTORS;

EID: 66749190028     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00111208     Document Type: Article

References (123)

1. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993; 328: 1230-1235.
2. Marshall NS, Wong KK, Liu PY, Cullen SR, Knuiman MW, Grunstein RR. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep 2008; 31: 1079-1085.
3. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep 2008; 31: 1071-1078.
4. Nieto FJ, Young TB, Lind BK, et al. Association of sleep- disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000; 283: 1829-1836.
5. Bixler EO, Vgontzas AN, Lin HM, et al. Association of hypertension and sleep-disordered breathing. Arch Intern Med 2000; 160: 2289-2295.
6. Peker Y, Kraiczi H, Hedner J, Loth S, Johansson A, Bende M. An independent association between obstructive sleep apnoea and coronary artery disease. Eur Respir J 1999; 14: 179-184.
7. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005; 353: 2034-2041.
8. Gami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 2004; 110: 364-367.
9. Wang H, Parker JD, Newton GE, et al. Influence of obstructive sleep apnea on mortality in patients with heart failure. J Am Coll Cardiol 2007; 49: 1625-1631.
10. Doherty LS, Kiely JL, Swan V, McNicholas WT. Long- term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. Chest 2005; 127: 2076-2084.
11. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-1053.
12. McNicholas WT, Bonsignore MR, the Management Committee of ECAB. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 2007; 29: 156-178.
13. Caples SM, Gami AS, Somers VK. Obstructive sleep apnea. Ann Intern Med 2005; 142: 187-197.
14. Williams A, Scharf SM. Obstructive sleep apnea, cardiovascular disease and inflammation - is NF-kB the key? Sleep Breath 2007; 11: 69-76.
15. Krieger J, Sforza E, Boudewijns A, Zamagni M, Petiau C. Respiratory effort during obstructive sleep apnea: role of age and sleep state. Chest 1997; 112: 875-884.
16. Ryan S, Taylor C, McNicholas W. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005; 112: 2660-2667.
17. Cahan C, Decker M, Strohl KP. Humoral correlates of sleep apnea: erythropoietin and hypoxemia. Prog Clin Biol Res 1990; 345: 317-322.
18. Cahan C, Decker MJ, Arnold JL, et al. Diurnal variations in serum erythropoietin levels in healthy subjects and sleep apnea patients. J Appl Physiol 1992; 72: 2112-2117.
19. Winnicki M, Shamsuzzaman A, Lanfranchi P, et al. Erythropoietin and obstructive sleep apnea. Am J Hypertens 2004; 17: 783-786.
20. Imagawa S, Yamaguchi Y, Higuchi M, et al. Levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea-hypopnea syndrome. Blood 2001; 98: 1255-1257.
21. Schulz R, Hummel C, Heinemann S, Seeger W, Grimminger F. Serum levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea and severe nighttime hypoxia. Am J Respir Crit Care Med 2002; 165: 67-70.
22. Lavie L, Kraiczi H, Hefetz A, Ghandour H, Perelman A, Hedner J, Lavie P. Plasma vascular endothelial growth factor in sleep apnea syndrome: effects of nasal continuous positive air pressure treatment. Am J Respir Crit Care Med 2002; 165: 1624-1628.
23. Lavie L, Lavie P. Ischemic preconditioning as a possible explanation for the age decline relative mortality in sleep apnea. Med Hypotheses 2006; 66: 1069-1073.
24. Lavie P, Lavie L, Herer P. All-cause mortality in males with sleep apnoea syndrome: declining mortality rates with age. Eur Respir J 2005; 25: 514-520.
25. He J, Kryger MH, Zorick FJ, Conway W, Roth T. Mortality and apnea index in obstructive sleep apnea. Experience in 385 male patients. Chest 1988; 94: 9-14.
26. Lavie P, Herer P, Peled R, Berger I, Yoffe N, Zomer J, Rubin AH. Mortality in sleep apnea patients: a multi- variate analysis of risk factors. Sleep 1995; 18: 149-157.
27. Marti S, Sampol G, Munoz X, et al. Mortality in severe sleep apnoea/hypopnoea syndrome patients: impact of treatment. Eur Respir J 2002; 20: 1511-1518.
28. Foster GE, Poulin MJ, Hanly PJ. Intermittent hypoxia and vascular function: implications for obstructive sleep apnoea. Exp Physiol 2007; 92: 51-65.
29. Dyugovskaya L, Lavie P, Lavie L. Phenotypic and functional characterization of blood yd T cells in sleep apnea. Am J Respir Crit Care Med 2003; 168: 242-249.
30. Minoguchi K, Tazaki T, Yokoe T, et al. Elevated production of tumor necrosis factor-a by monocytes in patients with obstructive sleep apnea syndrome. Chest 2004; 126: 1473-1479.
31. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 1997; 82: 1313-1316.
32. Vgontzas AN, Zoumakis E, Lin HM, Bixler EO, Trakada G, Chrousos GP. Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-a antagonist. J Clin Endocrinol Metab 2004; 89: 4409-4413.
33. Ryan S, Taylor C, McNicholas W. Predictors of elevated nuclear factor-kB-dependent genes in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2006; 174: 824-830.
34. Imagawa S, Yamaguchi Y, Ogawa K, et al. Interleukin-6 and tumor necrosis factor-a in patients with obstructive sleep apnea-hypopnea syndrome. Respiration 2004; 71: 24-29.
35. Dyugovskaya L, Polyakov A, Lavie P, Lavie L. Delayed neutrophil apoptosis in patients with sleep apnea. Am J Respir Crit Care Med 2008; 177: 544-554.
36. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 2002; 165: 934-939.
37. Dyugovskaya L, Lavie P, Hirsh M, Lavie L. Activated CD8+ T-lymphocytes in obstructive sleep apnoea. Eur Respir J 2005; 25: 820-828.
38. Dyugovskaya L, Lavie P, Lavie L. Lymphocyte activation as a possible measure of atherosclerotic risk in patients with sleep apnea. Ann N Y Acad Sci 2005; 1051: 340-350.
39. Lavie L, Dyugovskaya L, Lavie P. Sleep-apnea-related intermittent hypoxia and atherogenesis: adhesion molecules and monocytes/endothelial cells interactions. Atherosclerosis 2005; 183: 183-184.
40. Minoguchi K, Yokoe T, Tazaki T, et al. Increased carotid intima-media thickness and serum inflammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med 2005; 172: 625-630.
41. Sen R, Baltimore D. Inducibility of κ immunoglobulin enhancer-binding protein NF-kB by a posttranslational mechanism. Cell 1986; 47: 921-928.
42. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006; 441: 431-436.
43. Greenberg H, Ye X, Wilson D, Htoo AK, Hendersen T, Liu SF. Chronic intermittent hypoxia activates nuclear factor-kB in cardiovascular tissues in vivo. Biochem Biophys Res Commun 2006; 343: 591-596.
44. Kletsas D, Pratsinis H, Mariatos G, Zacharatos P, Gorgoulis VG. The proinflammatory phenotype of senescent cells: the p53-mediated ICAM-1 expression. Ann N Y Acad Sci 2004; 1019: 330-332.
45. Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN. Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 2006; 38: 1654-1661.
46. Ryan S, McNicholas WT, Taylor CT. A critical role for p38 map kinase in NF-kB signaling during intermittent hypoxia/reoxygenation. Biochem Biophys Res Commun 2007; 355: 728-733.
47. Htoo AK, Greenberg H, Tongia S, et al. Activation of nuclear factor-kB in obstructive sleep apnea: a pathway leading to systemic inflammation. Sleep Breath 2006; 10: 43-50.
48. Semenza G. Hydroxylation of HIF-1: oxygen sensing at he molecular level. Physiology 2004; 19: 176-182.
49. 2- dependent degradation domain via the ubiquitin-protea-some pathway. Proc Natl Acad Sci USA 1998; 95: 7987-7992.
50. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively down- regulating mitochondrial oxygen consumption. Cell Metab 2006; 3: 150-151.
51. Fandrey J. Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol 2004; 286: R977-R988.
52. Cummins EP, Taylor CT. Hypoxia-responsive transcription factors. Pflugers Arch 2005; 450: 363-371.
53. 2+/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. J Biol Chem 2005; 280: 4321-4328.
54. 2+ signaling, prolyl hydroxylases, and mTOR. J Cell Physiol 2008; 217: 674-685.
55. Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1a is essential for myeloid cell-mediated inflammation. Cell 2003; 112: 645-657.
56. Rius J, Guma M, Schachtrup C, et al. NF-kB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1a. Nature 2008; 453: 807-811.
57. van Uden P, Kenneth NS, Rocha S. Regulation of hypoxia-inducible factor-1a by NF-kB. Biochem J 2008; 412: 477-484.
58. Belaiba RS, Bonello S, Zahringer C, et al. Hypoxia up- regulates hypoxia-inducible factor-1a transcription by involving phosphatidylinositol 3-kinase and nuclear factor kB in pulmonary artery smooth muscle cells. Mol Biol Cell 2007; 18: 4691-4697.
59. Walmsley SR, Print C, Farahi N, et al. Hypoxia-induced neutrophil survival is mediated by HIF-1a-dependent NF-kB activity. J Exp Med 2005; 201: 105-115.
60. Scortegagna M, Cataisson C, Martin RJ, et al. HIF-1a regulates epithelial inflammation by cell autonomous NFkB activation and paracrine stromal remodeling. Blood 2008; 111: 3343-3354.
61. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kB/Rel in induction of nitric oxide synthase. J Biol Chem 1994; 269: 4705-4708.
62. Jung F, Palmer LA, Zhou N, Johns RA. Hypoxic regulation of inducible nitric oxide synthase via hypoxia inducible factor-1 in cardiac myocytes. Circ Res 2000; 86: 319-325.
63. Taylor CT. Interdependent roles for hypoxia inducible factor and nuclear factor-kB in hypoxic inflammation. J Physiol 2008; 586: 4055-4059.
64. Robbins P. Role of the peripheral chemoreflex in the early stages of ventilatory acclimatization to altitude. Respir Physiol Neurobiol 2007; 158: 237-242.
65. Serebrovskaya TV, Manukhina EB, Smith ML, Downey HF, Mallet RT. Intermittent hypoxia: cause of or therapy for systemic hypertension? Exp Biol Med (Maywood) 2008; 233: 627-650.
66. Kupper T, Schoffl V, Netzer N. Cheyne Stokes breathing at high altitude: a helpful response or a troublemaker? Sleep Breath 2008; 12: 123-127.
67. Marticorena E, Ruiz L, Severino J, Galvez J, Penaloza D. Systemic blood pressure in white men born at sea level: changes after long residence at high altitudes. Am J Cardiol 1969; 23: 364-368.
68. Mortimer EA Jr, Monson RR, MacMahon B. Reduction in mortality from coronary heart disease in men residing at high altitude. N Engl J Med 1977; 296: 581-585.
69. Powell F. The influence of chronic hypoxia upon chemoreception. Respir Physiol Neurobiol 2007; 157: 154-161.
70. Narkiewicz K, van de Borne PJ, Cooley RL, Dyken ME, Somers VK. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998; 98: 772-776.
71. Narkiewicz K, van de Borne PJ, Montano N, Dyken ME, Phillips BG, Somers VK. Contribution of tonic chemore- flex activation to sympathetic activity and blood pressure in patients with obstructive sleep apnea. Circulation 1998; 97: 943-945.
72. Narkiewicz K, van de Borne PJ, Pesek CA, Dyken ME, Montano N, Somers VK. Selective potentiation of peripheral chemoreflex sensitivity in obstructive sleep apnea. Circulation 1999; 99: 1183-1189.
73. Ryan S, Ward S, Heneghan C, McNicholas WT. Predictors of decreased spontaneous baroreflex sensitivity in obstructive sleep apnea syndrome. Chest 2007; 131: 1100-1107.
74. Semenza G. Regulation of physiological responses to continuous and intermittent hypoxiaby hypoxia-inducible factor 1. Exp Physiol 2006; 91: 803-806.
75. Berra E, Milanini J, Richard DE, et al. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol 2000; 60: 1171-1178.
76. Yu AY, Shimoda LA, Iyer NV, et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1a. J Clin Invest 1999; 103: 691-696.
77. Peng YJ, Yuan G, Ramakrishnan D, et al. Heterozygous HIF-1alpha deficiency impairs carotid body-mediated systemic responses and reactive oxygen species generation in mice exposed to intermittent hypoxia. J Physiol 2006; 577: 705-716.
78. Semenza GL, Prabhakar N. HIF-1-dependent respiratory, cardiovascular, and redox responses to chronic intermittent hypoxia. Antioxid Redox Signal 2007; 9: 1391-1396.
79. Lam SY, Tipoe GL, Liong EC, Fung ML. Differential expressions and roles of hypoxia-inducible factor-1a,-2a and -3a in the rat carotid body during chronic and intermittent hypoxia. Histol Histopathol 2008; 23: 271-280.
80. Fletcher EC, Lesske J, Behm R, Miller CC 3rd, Stauss H, Unger T., Carotid chemoreceptors, systemic blood pressure, and chronic episodic hypoxia mimicking sleep apnea. J Appl Physiol 1992; 72: 1978-1984.
81. Lesske J, Fletcher EC, Bao G, Unger T. Hypertension caused by chronic intermittent hypoxia--influence of chemoreceptors and sympathetic nervous system. J Hypertens 1997; 15: 1593-1603.
82. ReyS,DelRioR,AlcayagaJ,IturriagaR. Chronic intermittent hypoxia enhances cat chemosensory and ventilatory responses to hypoxia. J Physiol 2004; 560: 577-586.
83. Pawar A, Peng YJ, Jacono FJ, Prabhakar NR. Comparative analysis of neonatal and adult rat carotid body responses to chronic intermittent hypoxia. J Appl Physiol 2008; 104: 1287-1294.
84. Toffoli S, Feron O, Raes M, Michiels C. Intermittent hypoxia changes HIF-1a phosphorylation pattern in endothelial cells: unravelling of a new PKA-dependent regulation of HIF-1a. Biochim Biophys Acta 2007; 773: 1558-1571.
85. Martinive P, Defresne F, Bouzin C, et al. Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res 2006; 66: 11736-11744.
86. Stefanec T. Endothelial apoptosis: could it have a role in the pathogenesis and treatment of disease? Chest 2000; 117: 841-854.
87. Alvarez RJ, Gips SJ, Moldovan N, et al. 17b-estradiol inhibits apoptosis of endothelial cells. Biochem Biophys Res Commun 1997; 237: 372-381.
88. Haunstetter A, Izumo S. Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res 1998; 82: 1111-1129.
89. Hasdai D, Sangiori G, Spagnoli LG, et al. Coronary artery apoptosis in experimental hypercholesterolemia. Atherosclerosis 1999; 42: 317-325.
90. Barnes PJ, Karin M. Nuclear factor κB a pivotal transcription factor in chronic inflammatory diseases. NEngl J Med 1997; 336: 1066-1071.
91. El Solh AA, Akinnusi ME, Baddoura FH, Mankowski CR. Endothelial cell apoptosis in obstructive sleep apnea: a link to endothelial dysfunction. Am J Respir Crit Care Med 2007; 175: 1186-1191.
92. Martin K, Stanchina M, Kouttab N, Harrington EO, Rounds S. Circulating Endothelial cells and endothelial progenitor cells in obstructive sleep apnea. Lung 2008; 186: 145-150.
93. Jelic S, Padeletti M, Kawut SM, et al. Inflammation, oxidative stress, and repair capacity of the vascular endothelium in obstructive sleep apnea. Circulation 2008; 117: 2270-2278.
94. de la Pena M, Barcelo A, Barbe F, et al. Endothelial function and circulating endothelial progenitor cells in patients with sleep apnea syndrome. Respiration 2008; 76: 28-32.
95. Wolk R, Somers VK. Sleep and the metabolic syndrome. Exp Physiol 2007; 92: 67-78.
96. Hotamisligil GS, Speigelman BM. Tumor necrosis factor a: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-1278.
97. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-a, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200.
98. Coppack S. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 2001; 60: 349-356.
99. Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-a. Cytokine Growth Factor Rev 2003; 14: 447-455.
100. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347-355.
101. Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br J Nutr 2008; 100: 227-235.
102. Magalang UJ, Cruff JP, Rajappan R, et al. Intermittent hypoxia suppresses adiponectin secretion by adipocytes. Exp Clin Endocrinol Diabetes 2008; [Epub ahead of print PMID: 18563681].
103. Nakagawa Y, Kishida K, Kihara S, et al. Nocturnal reduction in circulating adiponectin concentrations related to hypoxic stress in severe obstructive sleep apnea-hypopnea syndrome. Am J Physiol Endocrinol Metab 2008; 294: E778-E784.
104. Kanbay A, Kokturk O, Ciftci TU, Tavil Y, Bukan N. Comparison of serum adiponectin and tumor necrosis factor-a levels between patients with and without obstructive sleep apnea syndrome. Respiration 2008; 76: 324-330.
105. Takahashi K, Chin K, Nakamura H, et al. Plasma thioredoxin, a novel oxidative stress marker, in patients with obstructive sleep apnea before and after nasal continuous positive airway pressure. Antioxid Redox Signal 2008; 10: 715-726.
106. Zhang XL, Yin KS, Li C, Jia EZ, Li YQ, Gao ZF. Effect of continuous positive airway pressure treatment on serum adiponectin level and mean arterial pressure in male patients with obstructive sleep apnea syndrome. Chin Med J (Engl) 2007; 120: 1477-1481.
107. Masserini B, Morpurgo PS, Donadio F, et al. Reduced levels of adiponectin in sleep apnea syndrome. J Endocrinol Invest 2006; 29: 700-705.
108. Zhang XL, Yin KS, Wang H, Su S. Serum adiponectin levels in adult male patients with obstructive sleep apnea hypopnea syndrome. Respiration 2006; 73: 73-77.
109. Harsch IA, Wallaschofski H, Koebnick C, et al. Adiponectin in patients with obstructive sleep apnea syndrome: course and physiological relevance. Respiration 2004; 71: 580-586.
110. ZhangXL,YinKS,MaoH,WangH,YangY.Serum adiponectin level in patients with obstructive sleep apnea hypopnea syndrome. Chin Med J (Engl) 2004; 117: 1603-1606.
111. Makino S, Handa H, Suzukawa K, et al. Obstructive sleep apnoea syndrome, plasma adiponectin levels, and insulin resistance. Clin Endocrinol (Oxf) 2006; 64: 12-19.
112. Sumi K, Chin K, Takahashi K, et al. Effect of nCPAP therapy on heart rate in patients with obstructive sleep apnoea-hypopnoea. QJM 2006; 99: 545-553.
113. Sharma SK, Kumpawat S, Goel A, Banga A, Ramakrishnan L, Chaturvedi P. Obesity, and not obstructive sleep apnea, is responsible for metabolic abnormalities in a cohort with sleep-disordered breathing. Sleep Med 2007; 8: 12-17.
114. Tauman R, Serpero LD, Capdevila OS, et al. Adipokines in children with sleep disordered breathing. Sleep 2007; 30: 443-449.
115. West SD, Nicoll DJ, Wallace TM, Matthews DR, Stradling JR. Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 2007; 62: 969-974.
116. Wolk R, Svatikova A, Nelson CA, et al. Plasma levels of adiponectin, a novel adipocyte-derived hormone, in sleep pnea. Obes Res 2005; 13: 186-190.
117. Yokoe T, Minoguchi K, Matsuo H, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003; 107: 1129-1134.
118. Hayashi M, Fujimoto K, Urushibata K, Takamizawa A, Kinoshita O, Kubo K. Hypoxia-sensitive molecules may modulate the development of atherosclerosis in sleep apnoea syndrome. Respirology 2006; 11: 24-31.
119. Kokturk O, Cifci TU, Mollarecep E, Cifci B. Elevated C- reactive protein levels and increased cardiovascular risk in patients with obstructive sleep apnea syndrome. Int Heart J 2005; 46: 801-809.
120. Saletu M, Nosiska D, Kapfhammer G, et al. Structural and serum surrogate markers of cerebrovascular disease in obstructive sleep apnea (OSA). Association of mild OSA with early atherosclerosis. J Neurol 2006; 253: 746-752.
121. Ryan S, Nolan GM, Hannigan E, Cunningham S, Taylor C, McNicholas WT. Cardiovascular risk markers in obstructive sleep apnoea syndrome and correlation with obesity.Thorax 2007; 62: 509-514.
122. McNicholas WT. Compliance with nasal CPAP therapy for obstructive sleep apnoea: how much is enough? Eur Respir J 1997; 10: 969-970.
123. Sin DD, Mayers I, Man GC, Pawluk L. Long-term compliance rates to continuous positive airway pressure in obstructive sleep apnea: a population-based study. Chest 2002; 121: 430-435.